Journal article
Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy
Clinical oncology (Royal College of Radiologists (Great Britain)), v 26(12), pp 776-780
01 Dec 2014
PMID: 25213299
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
To report 5 year prostate-specific antigen outcomes in men undergoing prostate brachytherapy with caesium 131 at a single institution.
All patients who underwent prostate brachytherapy with caesium 131 at our institution and had at least 24 months of follow-up were included in this study. The results are reported by risk group (low, intermediate and high) as well as by treatment received (monotherapy, combination therapy or trimodal therapy). The Phoenix definition (absolute nadir plus 2 ng/ml) was used to define biochemical freedom from disease (BFD).
Four hundred and eighty-five patients underwent prostate brachytherapy with caesium 131 at our institution and 367 patients had at least 24 months of follow-up and were included in this analysis. Using the Phoenix criteria, 5 year actuarial BFD was 96.0% for patients in the low-risk category, 92.7% for patients in the intermediate-risk category and 82.9% for patients in the high-risk category. By treatment category, 95.7% of men treated with monotherapy had BFD, 84.9% of men treated with combination therapy had BFD and 92.0% of men treated with trimodal therapy had BFD.
The present study showed that prostate brachytherapy with caesium 131 achieves excellent oncological outcomes at 5 years.
•PSA outcomes in men undergoing prostate brachytherapy with Cesium 131 are reported.•The study includes 367 who have at least 24 months of follow up.•Cesium 131 prostate brachytherapy with achieves excellent oncological outcomes.
Metrics
Details
- Title
- Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy
- Creators
- R.M. Benoit - University of PittsburghR.P. Smith - University of PittsburghS. Beriwal - University of Pittsburgh
- Publication Details
- Clinical oncology (Royal College of Radiologists (Great Britain)), v 26(12), pp 776-780
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000345444500009
- Scopus ID
- 2-s2.0-84911479509
- Other Identifier
- 991021897371404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology